Patent intelligence · US
US 9346759
Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor
Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadis…
Patent details — US 9346759
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 24, 2016
- Expiration
- May 19, 2036
- Applicant
- Almirall, S.A.
- Claims
- 31
- CPC classes
- A61K, A61K31/4704, A61K45/06, A61P
Quick answer
US 9346759 (Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor) is held by Almirall, S.A.. Status: granted. Granted May 24, 2016. Expires May 19, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Almirall, S.A.
- Grant date
- Expiration
- Claims
- 31
- CPC classes
- A61K, A61K31/4704, A61K45/06, A61P, A61P11/00, A61P11/06
More from Almirall, S.A.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 9346759?
US 9346759 (Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor) is held by Almirall, S.A.. Status: granted. Granted May 24, 2016. Expires May 19, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9346759?
Almirall, S.A. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 9346759 expire?
Our index shows an expiration date of May 19, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.